SK Biopharmaceuticals Co., Ltd.
High uncertainty:The valuation methods show significant disagreement (>100% spread). Treat the range as a rough guide rather than a precise estimate.
Bear Case (25th pct.)
-69.7% vs price
Base Case (Median)
-64.0% vs price
Bull Case (75th pct.)
-22.6% vs price
◇ = Current price | |Bear |Base | Bull
| Method | Est. Value | vs Price | Weight |
|---|---|---|---|
| DCF (Discounted Cash Flow) | $25014.11 | -71.5% | High (40%) |
| PE Comparable | $94767.75 | 7.8% | Medium (25%) |
| Growth Trajectory DCF | $102473.06 | 16.6% | Medium (20%) |
| Graham Number | $31616.00 | -64.0% | Medium (40%) |
| EV/EBITDA | $28205.50 | -67.9% | Medium (20%) |
| EV/FCF | $41334.33 | -53.0% | Medium (20%) |
| Earnings Power Value | $7360.27 | -91.6% | Medium (50%) |
Based on 7 out of 8 methods, 326030.KS appears overvalued at the current price of $87900.00. The base case fair value of $31616.00 implies 64.0% downside.
Bear/base/bull cases represent the 25th, 50th, and 75th percentile of available method estimates. This is not financial advice. Valuation is inherently uncertain.